PM
PharmaCyte Biotech, Inc.
PMCB · NASDAQ
$0.45 +8.08% (+$0.03)
1M -13.75%
Market Cap $4.41M
P/E Ratio -
Div. Yield -
ROE 60.42%
Piotroski F-Score Weak
2/9Valuation
90 /100
Cheap P/B 1.91x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 2,751.79%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 83.13%
ROE 60.42%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 40.30x
Int. coverage N/A
Stability
37 /100
Moderate Beta 0.66x
EPS volatility 250.18%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PMCB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Joshua N. Silverman
Employees
2
Headquarters
Las Vegas
Upcoming events
16 DEC
Earnings
Upcoming earnings report